Kurome Therapeutics advances with FDA-approved IND for KME-0584 in AML and HR MDS clinical trial
In a significant development for cancer research, Kurome Therapeutics Inc. has announced the U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for KME-0584, propelling the biotech firm into a Phase 1 clinical trial for patients with relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) and high-risk (HR) Myelodysplastic Syndromes (MDS). Slated […]